Investors holding shares in Rocket Lab find themselves at a precarious crossroads where explosive growth meets a daunting valuation. On paper, the company’s trajectory...
As investors shake off a surprisingly resilient September, experts are warning that the transition into October could bring unexpected turbulence. While the previous month...
Capitol Hill remains a place where rhetoric often clashes with reality, particularly when it comes to the promises of transparency and fairness for the...
The biotechnology sector is feeling the aftershocks of a significant clinical setback following an unexpected failure from pharmaceutical giants Novartis and Ionis Pharmaceuticals. Investors...